Mineralys Therapeutics Releases Positive Phase 2 Trial Data for Lorundrostat

Mineralys Therapeutics has published full Phase 2 Explore-CKD trial results for lorundrostat in Kidney International. The aldosterone synthase inhibitor significantly reduced systolic blood pressure, albuminuria, and proteinuria in patients with uncontrolled hypertension, chronic kidney disease, and albuminuria. This suggests potential kidney function benefits for a challenging patient population.